The Natural Selection of Herpesviruses and Virus-Specific NK Cell Receptors

doi:10.3390/v1030362

Viruses. 2009 December; 1(3): 362–382.

Published online 2009 October 13. doi: 10.3390/v1030362

PMCID: PMC2819288

NIHMSID: NIHMS172466

The Natural Selection of Herpesviruses and Virus-Specific NK Cell Receptors

Joseph C. Sun and Lewis L. Lanier^*

Department of Microbiology and Immunology and the Cancer Research Institute, University of California, San Francisco, CA 94143, USA

^*Author to whom correspondence should be addressed; E-Mail: lewis.lanier/at/ucsf.edu.

Received August 14, 2009; Revised October 13, 2009; Accepted October 13, 2009.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

This article has been cited by other articles in PMC.

Abstract

During the co-evolution of cytomegalovirus (CMV) and natural killer (NK) cells, each has evolved specific tactics in an attempt to prevail. CMV has evolved multiple immune evasion mechanisms to avoid detection by NK cells and other immune cells, leading to chronic infection. Meanwhile, the host has evolved virus-specific receptors to counter these evasion strategies. The natural selection of viral genes and host receptors allows us to observe a unique molecular example of “survival of the fittest”, as virus and immune cells try to out-maneuver one another or for the virus to achieve détente for optimal dissemination in the population.

Keywords: NK cells, cytomegalovirus, evolution

Introduction

During the course of evolution, the mammalian immune system has learned to adapt in order to defend the host against invading pathogens. Over time, lymphocytes of the immune system have acquired antigen-specific receptors as part of their arsenal to provide host immune surveillance against foreign substances and combat infectious agents. Some receptors, which arise by gene rearrangement and somatic hypermutation, can be exquisitely specific for processed protein fragments presented on major histocompatibility complex (MHC) molecules (in the case of T cells) or entire pathogen proteins (in the case of B cells and antibodies). Other receptors on innate immune cells, such as dendritic cells and macrophages, are germline-encoded, such as the pattern recognition receptors (PRR), and recognize motifs or conserved molecular patterns present on microorganisms. Natural killer (NK) cells possess many other activating and inhibitory receptors, and specific ligation of these receptors determines whether or not NK cells become activated (reviewed in [1]). Recently, several activating receptors on NK cells have been shown to recognize pathogen components, but only a handful of these receptor-ligand interactions have been characterized. In addition, NK cells possess the activating NKG2D receptor, which recognizes host-encoded MHC class I-related proteins that are expressed on “stressed” cells, including virus-infected and transformed cells[1,2].

Whereas antibodies and B cells can recognize the intact pathogen, T cells require the pathogen components to be processed into short peptide fragments by antigen-presenting cells, and then the primed effector T cells require the pathogen-infected cells to present these pathogen-encoded peptides – MHC complexes to be displayed on the surface of the infected cell for T cell recognition and response. The means by which NK cells recognize certain pathogens has not been entirely elucidated. In mammals, there are different families of receptors on NK cells that serve similar functions. In mice and humans, convergent evolution has resulted in the Ly49 and KIR (Killer cell Immunoglobulin-like Receptor) families of receptors, respectively, both containing inhibitory members that recognize host MHC class I and activating receptors that might detect pathogen-infected cells[1]. To date, the ligands of most of the activating receptors have not been well characterized, but some are thought to be proteins specifically encoded by pathogens. Because we are constantly bombarded with environmental pathogens, there is evidence that selective pressures from virulent microbes have caused the immune system in higher organisms to evolve accordingly. For example, African population studies examining areas historically endemic for malaria demonstrated that Plasmodium falciparum infection in humans has been a driving force for the selection of various host immune system genes, such as certain human leukocyte antigen (HLA) alleles, important for protection against infection [3,4].

The selective pressures that drive cells of the immune system to change over time are at work on the pathogen as well. In order to avoid immune detection and survive, viruses have adopted many immune evasion strategies such as blocking expression of molecules (MHC class I and NKG2D ligands) that “announce” the presence of infection or stress, and at the same time viruses carry in their genomes many decoy molecules (such as MHC class I analogs) that can inhibit cells of the immune system from becoming activated (reviewed in [5]). Only by delaying the response mounted by the immune cells or evading the immune system entirely can the virus ensure its own propagation and survival. This review will discuss several known NK cell receptor-pathogen interactions, focusing specifically on cytomegalovirus infections in mouse and human.

Cytomegaloviruses evade the immune system

The goal of CMV is to avoid elimination by the host immune response so that the virus can persist and be optimally disseminated in the host species population. To achieve this objective CMV, a large double-stranded DNA virus in the β-herpesvirus family, has evolved a large number of genes that prevent recognition of infected cells by the immune system.

During viral infection, CD8⁺ T cells can recognize viral peptides presented on MHC class I and mount a robust response by eliminating infected cells. Thus, CMV would benefit by blocking the pathways leading to host presentation of viral peptides. Many CMV gene products inhibit the presentation of viral proteins on MHC class I [5,6]. The viral proteins m04, m06, and m152 found in MCMV disrupt the MHC class I synthesis pathway (m152 causes MHC class I retention in the pre-Golgi compartment and m06 directs it to the lysosomes for degradation) and modulate antigen presentation (m04 escorts select MHC class I molecules to the cell surface) [7–12]. Similarly, HCMV US2, US3, US6, and US11 downregulate MHC class I presentation at different stages of biosynthesis; US2 and US11 drive retro-translocation of MHC class I from ER to the cytosol leading to degradation, US3 causes its retention in the ER, and US6 inhibits TAP-mediated transport of processed peptides for loading onto MHC class I [13–19]. These MCMV- and HCMV-encoded proteins and their location of function are depicted in Figure 1.

Figure 1.

MCMV and HCMV proteins interfere with MHC class I presentation and host recognition of virally infected cells. MCMV-encoded glycoproteins (shown in orange) inhibit the biosynthesis and expression of mouse MHC class I molecules: m06 binds MHC class I in (more ...)

During viral infection, another mechanism by which the host can communicate “danger” to the immune system is through the expression of stress molecules. In humans, these stress markers include the MIC and ULBP (also referred to as RAET1) family of molecules, which are ligands for the activating NKG2D receptor on NK cells and T cells [20–23]. In mice, the RAE-1 family of gene products, along with MULT1 and H60, constitute the stress-induced ligands of NKG2D, which are strongly induced during viral infection[24–27]. Although the mRNA transcripts of these NKG2D ligands are highly upregulated during infection, MCMV and HCMV have evolved gene products to limit the protein expression of NKG2D ligands. In MCMV, the viral protein m152, in addition to modulating MHC class I expression, interferes with expression of all five members of the RAE-1 family of glycoproteins [28], and the m145 and m155 proteins have been shown to downregulate MULT1 and H60 expression, respectively [29–31]. More recently, the viral protein m138 (also known as fcr-1) has been shown to play a redundant role, and is able to promiscuously suppress surface expression of NKG2D ligands MULT1, H60, and RAE-1ε [32,33]. Furthermore, m138 can also inhibit the expression of the costimulatory molecule CD80 (B7-1) on dendritic cells, leading to reduced CD8⁺ T cell priming against MCMV [34]. In HCMV, the viral glycoprotein UL16 downmodulates expression of the human NKG2D ligands MICB, ULBP1, and ULBP2 [23,35], and the virus-encoded UL142 shuts down expression of certain alleles of MICA to prevent NK cell recognition and killing [36,37]. More recently, Mandelboim and colleagues showed that HCMV also encodes a microRNA (named hcmv-miR-UL112) that specifically targets MICB transcripts for degradation, leading to decreased NKG2D binding and NK cell-mediated lysis of infected target cells[38]. These MCMV and HCMV-encoded proteins are depicted in Figure 2. Undoubtedly, additional virus-encoded proteins and microRNAs will be discovered that inhibit the ability of infected cells to signal the presence of the virus to NK cells and CD8⁺ T cells.

Figure 2.

MCMV and HCMV proteins interfere with expression of NKG2D ligands and host recognition of virally infected cells. (A) MCMV-encoded glycoproteins (shown in orange) inhibit the expression of mouse NKG2D ligands: m152 interferes with expression of all five (more ...)

Both MCMV and HCMV possess genes encoding MHC class I-like molecules in their genomes. These homologs of MHC class I might serve as decoy ligands and allow the virus to hide from NK cells, which can sense the loss of MHC class I on potential target cells. Because inhibitory NK cell receptors, such as the mouse Ly49 receptors and the human KIRs, interact with MHC class I molecules, herpesviruses carrying homologues of class I might attempt to shut down the NK cell response.

NK cell-mediated resistance to MCMV in mice is genetically controlled. Previous genetic mapping studies showed that resistance to MCMV was restricted to the C57BL/6 and MA/My strains of mice [39–42]. The CMV-resistance gene(s), designated Cmv1^r, is located on the distal end of mouse chromosome 6 [42–46], and this Cmv1^r gene in C57BL/6 mice enables NK cells to protect mice from an otherwise lethal infection [41,47]. The precise molecular interactions between mouse NK cell receptors and viral elements on MCMV-infected cells have been elucidated, providing insights into the mechanisms behind NK cell-mediated anti-viral responses [48]. Similarly, a specific NK cell subset has been identified in humans that preferentially expands during HCMV infection, suggesting the parallel evolution of immune pathways in mouse and man that target members of the herpesvirus family.

Ly49H and MCMV

The NK cell response against MCMV constitutes arguably the most well-characterized example of a virus driving the evolution of immune receptors, and reciprocally the host immune system selecting for more virulent strains of a virus. In C57BL/6 mice, NK cells bearing the activating Ly49H receptor confer resistance against MCMV infection. Genetic linkage analysis, in conjunction with depletion of specific NK cell subsets by monoclonal antibodies, demonstrated that CMV-resistance is mediated by the Ly49H receptor, which is encoded by the Cmv-1 locus [40,49,50]. The Ly49H receptor cannot signal on its own, but pairs via its transmembrane domain with an adapter molecule DAP12, which contains immunoreceptor tyrosine-based activation motifs (ITAMs) [51]. More recently, Ly49H has been shown to also pair with DAP10 [52–54], another adaptor molecule containing a YINM motif activating PI3-kinase and Vav1; signaling via DAP10 enhances DAP12-driven NK cell-mediated functions [53]. Thus, when Ly49H⁺ NK cells encounter MCMV-infected cells, the Ly49H receptor signals via DAP12 (augmented by DAP10), leading to NK cell activation, secretion of cytokines, and killing of the infected target cells (Figure 3). Not surprisingly, DAP12-deficient mice and DAP12 + DAP10 doubly-deficient mice are susceptible to MCMV infection, due to diminished expression of Ly49H and an inability to transmit a full activation signal [53,55]. Similarly, Ly49H-deficient mice on a C57BL/6 background, which possess NK cells unable to respond specifically against MCMV, are susceptible to viral infection [56,57]. Conversely, transgenic expression of Ly49H confers protection against MCMV in genetically susceptible BALB/c mice [58]. Thus, the presence of the Ly49H receptor (with its associated signaling subunits) is necessary and sufficient to provide NK cell-mediated resistance against MCMV infection.

Figure 3.

MCMV-encoded m157 leads to activation or inhibition depending on NK cell receptor expression. Following MCMV infection of a target cell (step 1), the m157 glycoprotein is expressed (step 2). NK cells from C57BL/6 mice express the activating Ly49H receptor (more ...)

The m157 glycoprotein encoded by MCMV was identified as a ligand of Ly49H using NFAT-GFP reporter cells expressing the Ly49H – DAP12 receptor complex [59,60]. Direct binding of m157 to Ly49H was further confirmed by using m157-Ig fusion proteins, which stained Ly49H transfectants and NK cells endogenously expressing Ly49H [59]. Additionally, Ly49H⁺ NK cells were able to mediate cytotoxicity and secrete IFN-γ when co-cultured with target cells expressing m157, and these effector functions were abrogated by a neutralizing anti-Ly49H antibody [59,60]. The expression of m157 in fibroblasts infected with MCMV is not dependent on β₂-microglobulin (β₂m) or TAP [59], demonstrating that m157 does not associate with MHC class I and is stably expressed on the surface of infected cells without a binding partner. The crystal structure of m157 has revealed homology to the nonclassical MHC class I family of molecules such as CD1d, H2-M3, and T22 [61]. When Ly49H-bearing NK cells detect m157 on MCMV-infected cells, this interaction leads to NK cell activation and effector function, followed by robust proliferation of Ly49H⁺ NK cells [62,63] (Figure 3). Not surprisingly, MCMV mutants lacking m157 are more virulent, resulting in higher viral titers in C57BL/6 mice following infection [64].

The retention of a viral protein that specifically activates an immune response appears counterproductive to survival of the virus, so why would MCMV retain such a seemingly detrimental component in its genome? m157 is a MHC class I homolog; therefore, it may have evolved to engage inhibitory NK cell receptors and thus counteract viral proteins involved in blocking MHC class I expression leading to “missing self” recognition. Cytomegaloviruses possess many genes encoding immunoevasins that interfere with antigen presentation by preventing the assembly of MHC class I, or by retaining and degrading MHC class I (reviewed in [5,65]). Although inhibiting MHC class I presentation might protect the virus from a CD8⁺ T cell response (Figure 4A), the loss of MHC class I proteins on the surface of virus-infected cells could potentially lead to destruction by NK cells [66,67] (Figure 4B). Thus, downregulation of MHC class I by CMV might have forced the evolution of CMV-encoded class I-like homologs to engage inhibitory receptors on NK cells [68,69]. Thus, sensing of the viral MHC class I decoys that replace the vacated host MHC class I might suppress the NK cell response (Figure 4C). In certain strains of mice, for example 129/J, m157 binds the inhibitory Ly49I receptor [59], potentially impairing the ability of NK cells expressing Ly49I to respond to MCMV infection (Figure 3). Ly49I binds to m157 with higher affinity than with the Ly49H receptor [61]. Moreover, Ly49I binds to m157 with higher affinity than to the H2 ligand of Ly49I [61]. A comparison of the Ly49i and Ly49h genes indicates that Ly49i is evolutionary older and that Ly49h arose from a Ly49i gene by gene duplication and conversion [70]. During its evolution from Ly49I, Ly49H retained the ability to bind m157 (Figure 4D), but lost affinity for binding H2 ligands. Remarkably, due to selective pressure exerted by the virus, the host adapted [70–72]. Natural selection dictates that the virus will continue to mutate (Figure 4E), and this is evidenced by the high degree of polymorphism found in the m157 gene from MCMV strains isolated from mice in the wild [73]. Furthermore, serial passage of MCMV in C57BL/6 mice leads to the escape of viral variants containing loss-of-function mutations in m157 [73,74]. Together, these studies provide evidence that NK cells bearing specific activating receptors can exert ample selective pressure on a DNA virus, such that it undergoes rapid mutation at the molecular level in order to ensure its ability to evade immune surveillance and allow it to propagate.

Figure 4.

Selective pressures drive the evolution of virus and host genes. A model predicting the influence of natural selection on evolution of herpesviruses and NK cell receptors: (A) During infection, viral peptides presented on MHC class I are recognized by (more ...)

Ly49P and MCMV

Although MA/My mice do not possess the Ly49h gene, these mice are resistant to MCMV. Vidal and colleagues demonstrated that epistatic interactions between the activating NK cell receptor Ly49P and host MHC class I H2-D^k confer resistance to MCMV in MA/My mice [39], which possess both. Genetic mapping studies revealed that to resist MCMV infection mice must inherit both the Ly49p and H2d^k genes from their parents [39]. Similar to the Ly49H receptor, Ly49P associates with and signals through DAP12; however, unlike m157 detection by Ly49H, the virus-derived ligand recognized by Ly49P is not as straightforward. NFAT-GFP reporter cells expressing Ly49P and DAP12 were activated only when co-cultured with MCMV-infected fibroblasts that expressed H2-D^k and recognition was blocked by a neutralizing anti-H2-D^k antibody, but not antibody to H2-K^k [39]. Thus, Ly49P recognition of MCMV is MHC-restricted, similar to MHC-restriction of T cells.

Recently, Vidal and colleagues identified a viral component required for Ly49P recognition of MCMV-infected cells. The virus-encoded m04 glycoprotein (also known as gp34) is crucial to NK cell-mediated control of viral replication, as a m04 deletion mutant of MCMV abrogated resistance against infection in MA/My mice [75]. Thus, both H2-D^k and m04 are required for NK cell-mediated protection against MCMV infection. Using chimeric molecules of H2, where the α1, α2, and α3 domains of D^b and D^k were systematically exchanged, Vidal and colleagues demonstrated that the peptide-binding α1 and α2 domains of H2-D^k are absolutely required for recognition by Ly49P reporter cells [75]. However, Ly49P reporter cells were not activated when co-cultured with fibroblasts only expressing m04 and H2-D^k in the absence of MCMV infection [75]. Therefore, the ligand recognized by Ly49P appears to require additional elements conferred by MCMV infection. Together, these data suggest that unlike the ability of m157 to directly activate Ly49H⁺ NK cells, m04 is required but not sufficient for recognition by Ly49P. Interestingly, m04 associates with MHC class I proteins in MCMV-infected cells [7–9,76], and is able to inhibit antigen presentation without reducing the amount of MHC class I at the cell surface [77,78].

What is the nature of the ligand for Ly49P? Although prior studies using recombinant Ly49P demonstrated low affinity binding of Ly49P to H-2, Ly49P reporter cells do not recognize fibroblasts expressing H2-D^k with endogenous peptides [75] (Figure 5A). During MCMV infection, TAP, β₂m, and the peptide binding groove (α1 and α2 domains) of H2-D^k are all required for Ly49P interaction, suggesting that Ly49P might recognize a peptide fragment of m04 bound to H2-D^k in manner similar to TCR recognition of peptide-MHC class I complexes (Figure 5B). Although this hypothesis remains plausible, the transfection of m04 into H2-D^k-bearing fibroblasts without MCMV infection did not stimulate Ly49P reporter cells [75]. By interactions requiring its transmembrane domain, m04 has been shown to physically associate with β₂m and MHC class I heavy chain in the endoplasmic reticulum prior to transport to the cell surface [8,9,76]. During MCMV infection, m04 could conceivably modify the conformation of H2-D^k so that Ly49P can recognize an altered form of H2-D^k (Figure 5C). Although expression of m04 in MCMV-infected fibroblasts does not appear to hinder recognition by CD8⁺ T cells (implying minimal allosteric changes in MHC class I) [79], NK cell recognition of a m04-associated H2-D^k protein could be entirely different, and does not exclude normal binding of peptides to the MHC class I groove or recognition of viral peptide-MHC by the T cell receptor. Alternatively, Ly49P might recognize the entire m04/H2-D^k complex, with the extracellular C-type lectin-like domains of Ly49P contacting both the intact viral m04 protein and the H2-D^k molecule (Figure 5D). Crystallization of the receptor bound to the ligand complex will reveal the nature of the viral ligand, as well as the specific amino acid residues on H2-D^k that are required both for m04 association and for Ly49P recognition during MCMV infection.

Figure 5.

Possible mechanisms behind Ly49P recognition of m04 and H2-D^k during MCMV infection. (A) In the absence of MCMV infection, DAP12-associated Ly49P does not interact with MHC class I H2-D^k presenting endogenous peptides. (B) During MCMV infection, Ly49P-bearing (more ...)

Similar to the extensive polymorphism observed in the m157 gene found in MCMV isolates from wild mice, the high degree of variability of the m04 amino acid sequence in multiple strains of MCMV suggests that mutation of this gene constitutes a mechanism by which the virus responds to selective pressures mediated by the host immune system [80]. Not surprisingly, the highest degree of polymorphism was found to reside in the extracellular domains of the m04 protein (where Ly49P might contact m04), whereas the transmembrane and cytoplasmic regions remained relatively conserved [80]. Selective pressure and consequent evolution of m04 in MCMV strains from wild mice suggest that the host immune system can drive rapid mutation in specific viral proteins.

If the m04 protein confers recognition by Ly49P and enhances killing of infected cells, why does MCMV retain such a protein? Three possibilities exist. First, m04 might counteract the diminished cell surface expression of MHC class I mediated by the viral glycoproteins m152 and m06, which retain and mediate degradation of MHC class I proteins, respectively [7,10–12]. Because both m152 and m06 result in the loss of MHC class I on the cell surface, this might render MCMV-infected cells more susceptible to killing by NK cells able to sense “missing self”. Secondly, because m04 can selectively escort and stabilize MHC class I on the surface of infected cells, inhibitory NK cell receptors might gain more access to MHC class I, leading to suppression of NK cell responses. Several MHC class I molecules (including H2-K^b and H2-D^b) have been shown to form complexes with m04 [8,9], and these same MHC class I molecules have been shown to be specific ligands for different inhibitory NK cell receptors, including Ly49A, Ly49C, Ly49I, Ly49J, and Ly49V [81–84]. Lastly, it has been recently proposed that the m04 regulation of antigen presentation may enhance adaptive immune responses leading to host survival [85]; the outcome, although favorable to the host, may benefit the virus as well, allowing MCMV to be disseminated within the population.

CD94-NKG2C and HCMV

The first evidence that NK cells in humans were important for specific protection against cytomegalovirus came in 1989, when Biron and colleagues described a case of severe herpesvirus infection in a child lacking NK cells [86]. Unlike in the mouse models of cytomegalovirus infection described above, no specific viral ligands or NK cell receptors has yet been identified and characterized in HCMV. However, Lopez-Botet and colleagues have described the expansion of a specific subset of NK cells in response to HCMV. In the initial study, a substantial increase in the percentage of CD94-NKG2C receptor-expressing NK cells was observed in HCMV-seropositive individuals compared to control healthy adult blood donors [87]. One of the many difficulties of studying infectious diseases in humans is that it is hard to know when infection begins; therefore broadly characterizing immune cell subsets of HCMV-seropositive individuals only gives us snapshots of the immune response occurring days or months or even years after infection. Nonetheless, greater than 25% of the NK cells in HCMV-seropositive individuals expressed the activating NKG2C receptor, whereas the same subset of NK cells is rare (less than 2%) in seronegative subjects [87,88]. No such correlation between NK cell receptor expression and HCMV seropositivity was found for the related inhibitory NKG2A receptor [87,88]. Kuijpers and colleagues recently corroborated these results in a report describing preferential expansion of NKG2C⁺ NK cells in an immunodeficient child acutely infected with HCMV [89]. In this individual case, the time course of infection could be approximated and the peak of viremia closely correlated with the highly elevated NK cell numbers. Interestingly, the magnitude and kinetics of NK cell expansion and contraction closely resembles our recent measurements in the mouse Ly49H⁺ NK cell response following MCMV infection [63].

The human CD94-NKG2C receptor complex, expressed on NK cells and certain subsets of T cells, belongs to the killer C-type lectin-like receptor (KLR) family encoded in the NK cell gene complex on human chromosome 12 [46], and includes the NKG2A and NKG2C molecules which covalently associate with CD94 [90–94]. The CD94-NKG2A heterodimer is an inhibitory receptor that recruits the phosphatase SHP-1 via the immunoreceptor tyrosine-based inhibitory motif (ITIM) found in the cytoplasmic tail of NKG2A [95–98]. In contrast, the CD94-NKG2C heterodimer is activating, signaling via the associated ITAM-containing DAP12 subunit [99]. Both the inhibitory NKG2A and the activating NKG2C bind to a nonclassical MHC class Ib molecule HLA-E [100–102], which presents leader peptides derived from certain HLA-A, -B, -C, and -G proteins [100,103–105]. The affinity of NKG2A for HLA-E is 6-fold higher than the affinity of NKG2C. HLA-E is selectively resistant to downmodulation by the HCMV proteins that interfere with classical HLA class I expression. A leader segment from the UL40 HCMV protein can bind HLA-E, potentially inhibiting activation of CD94-NKG2A-bearing NK cells during HCMV infection [106–109]. Perhaps because of its restricted peptide-binding ability, HLA-E does not induce a robust CD8⁺ T cell response. Therefore, by selectively preserving expression of HLA-E, HCMV might avoid CTL detection, yet suppress NK cell-mediated responses (Figure 6).

Figure 6.

NK cell recognition of HCMV-encoded proteins during infection. The HCMV-encoded UL40 protein contains an epitope (from the UL40 leader sequence) that is bound by HLA-E and presented at the surface of virally infected cells. Binding of UL40 peptide/HLA-E (more ...)

NKG2C might represent the host’s response to CMV’s evasive maneuvers targeting NKG2A. Analysis of the genes encoding NKG2A and NKG2C in primates spanning greater than 35 million years of evolution suggests that both have been undergoing a “positive” selection indicative of host-pathogen struggles [110]. Is viral modulation of HLA-E enough to drive selection of a NKG2C receptor specific for HCMV?

The HCMV-encoded UL18 glycoprotein has structural homology to MHC class I, even associating with β₂m [69,111]. UL18 binds with high affinity to leukocyte immunoglobulin-like receptor-1 (LIR-1) (also named LILRB1, CD85j, and ILT2), expressed in high amounts on monocytes and macrophages, B cells, and a subset of NK cells [112,113] (Figure 6). UL18 binds LIR-1 with a 3-log higher affinity than HLA class I [114]. Curiously, fibroblasts infected with a mutant HCMV lacking UL18 were found to be less susceptible to NK cell-mediated lysis than fibroblasts infected with wildtype strains of HCMV [115], suggesting that UL18 might enhance, rather than inhibit, NK cell activation. However, expansion of NKG2C⁺ NK cells in vitro was not abrogated when co-cultured with fibroblasts infected with mutant virus lacking UL18 compared to fibroblasts infected with strains containing UL18 [115]. Recent studies have demonstrated that NKG2C, but not NKG2A, weakly binds UL18 (K_D ~10–100 μM) [110]. Nonetheless, as yet there is no direct evidence that NK cells expressing a CD94-NKG2C receptor directly recognize UL18 as a functional ligand.

Concluding Remarks

Altogether, these findings show that immune surveillance by NK cells drives the selection of viral genes, and the ability of cytomegalovirus to reciprocally shape the NK cell receptor repertoire. Is this interplay between NK cells and CMV unique to CMV? As yet, there is no evidence that the NK cell receptors recognizing CMV, such as Ly49H or Ly49P, are involved in the control of any other viral pathogens. Reciprocally, viral proteins similar to m157 have not been detected, at least by computationally searching the genomes of any other pathogens. Unlike B cells and T cells that can generate new receptors by somatic gene recombination, NK cells possess only those receptors encoded by the germline. Therefore, selection of these receptors must act at the population level in the species, not within the individual. The remarkable diversity of the murine Ly49 genes and primate KIR genes suggests an intriguing ongoing interaction between the host and pathogens. Perhaps the microbes of most interest to NK cells will be those pathogens, such as herpesvirus, that are persistent in the host and require constant vigilance.

Acknowledgments

We thank Carrie Sun for generating the figures. J.C.S. is an Irvington Postdoctoral Fellow of the Cancer Research Institute and L.L.L. is an American Cancer Society Professor and is supported by NIH grants AI066897, AI068129, CA095137, and AI64520.

References and Notes

1. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225–274. [PubMed]

2. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3:781–790. [PubMed]

3. Gilbert SC, Plebanski M, Gupta S, Morris J, Cox M, Aidoo M, Kwiatkowski D, Greenwood BM, Whittle HC, Hill AV. Association of malaria parasite population structure, HLA, and immunological antagonism. Science. 1998;279:1173–1177. [PubMed]

4. Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM. Common west African HLA antigens are associated with protection from severe malaria. Nature. 1991;352:595–600. [PubMed]

5. Mocarski ES., Jr Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol. 2002;10:332–339. [PubMed]

6. Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol. 2008;8:259–268. [PMC free article] [PubMed]

7. Kavanagh DG, Gold MC, Wagner M, Koszinowski UH, Hill AB. The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J Exp Med. 2001;194:967–978. [PMC free article] [PubMed]

8. Kavanagh DG, Koszinowski UH, Hill AB. The murine cytomegalovirus immune evasion protein m4/gp34 forms biochemically distinct complexes with class I MHC at the cell surface and in a pre-Golgi compartment. J Immunol. 2001;167:3894–3902. [PubMed]

9. Kleijnen MF, Huppa JB, Lucin P, Mukherjee S, Farrell H, Campbell AE, Koszinowski UH, Hill AB, Ploegh HL. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J. 1997;16:685–694. [PubMed]

10. Oliveira SA, Park SH, Lee P, Bendelac A, Shenk TE. Murine cytomegalovirus m02 gene family protects against natural killer cell-mediated immune surveillance. J Virol. 2002;76:885–894. [PMC free article] [PubMed]

11. Reusch U, Muranyi W, Lucin P, Burgert HG, Hengel H, Koszinowski UH. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J. 1999;18:1081–1091. [PubMed]

12. Ziegler H, Thale R, Lucin P, Muranyi W, Flohr T, Hengel H, Farrell H, Rawlinson W, Koszinowski UH. A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity. 1997;6:57–66. [PubMed]

13. Ahn K, Gruhler A, Galocha B, Jones TR, Wiertz EJ, Ploegh HL, Peterson PA, Yang Y, Fruh K. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity. 1997;6:613–621. [PubMed]

14. Barel MT, Ressing M, Pizzato N, van Leeuwen D, Le Bouteiller P, Lenfant F, Wiertz EJ. Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation. J Immunol. 2003;171:6757–6765. [PubMed]

15. Gruhler A, Peterson PA, Fruh K. Human cytomegalovirus immediate early glycoprotein US3 retains MHC class I molecules by transient association. Traffic. 2000;1:318–325. [PubMed]

16. Hengel H, Koopmann JO, Flohr T, Muranyi W, Goulmy E, Hammerling GJ, Koszinowski UH, Momburg F. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity. 1997;6:623–632. [PubMed]

17. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, Ploegh HL. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A. 1996;93:11327–11333. [PubMed]

18. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell. 1996;84:769–779. [PubMed]

19. Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR, Rapoport TA, Ploegh HL. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature. 1996;384:432–438. [PubMed]

20. Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A. 1994;91:6259–6263. [PubMed]

21. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727–729. [PubMed]

22. Chalupny NJ, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D. ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun. 2003;305:129–135. [PubMed]

23. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123–133. [PubMed]

24. Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol. 2002;169:4079–4083. [PubMed]

25. Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH, Lanier LL. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 2000;12:721–727. [PubMed]

26. Diefenbach A, Hsia JK, Hsiung MY, Raulet DH. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol. 2003;33:381–391. [PubMed]

27. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413:165–171. [PubMed]

28. Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES, Lanier LL. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med. 2003;197:1245–1253. [PMC free article] [PubMed]

29. Hasan M, Krmpotic A, Ruzsics Z, Bubic I, Lenac T, Halenius A, Loewendorf A, Messerle M, Hengel H, Jonjic S, Koszinowski UH. Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein. J Virol. 2005;79:2920–2930. [PMC free article] [PubMed]

30. Krmpotic A, Hasan M, Loewendorf A, Saulig T, Halenius A, Lenac T, Polic B, Bubic I, Kriegeskorte A, Pernjak-Pugel E, Messerle M, Hengel H, Busch DH, Koszinowski UH, Jonjic S. NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med. 2005;201:211–220. [PMC free article] [PubMed]

31. Lodoen MB, Abenes G, Umamoto S, Houchins JP, Liu F, Lanier LL. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J Exp Med. 2004;200:1075–1081. [PMC free article] [PubMed]

32. Arapovic J, Lenac Rovis T, Reddy AB, Krmpotic A, Jonjic S. Promiscuity of MCMV immunoevasin of NKG2D: m138/fcr-1 down-modulates RAE-1varepsilon in addition to MULT-1 and H60. Mol Immunol. 2009 [PubMed]

33. Lenac T, Budt M, Arapovic J, Hasan M, Zimmermann A, Simic H, Krmpotic A, Messerle M, Ruzsics Z, Koszinowski UH, Hengel H, Jonjic S. The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med. 2006;203:1843–1850. [PMC free article] [PubMed]

34. Mintern JD, Klemm EJ, Wagner M, Paquet ME, Napier MD, Kim YM, Koszinowski UH, Ploegh HL. Viral interference with B7-1 costimulation: a new role for murine cytomegalovirus fc receptor-1. J Immunol. 2006;177:8422–8431. [PubMed]

35. Bacon L, Eagle RA, Meyer M, Easom N, Young NT, Trowsdale J. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol. 2004;173:1078–1084. [PubMed]

36. Chalupny NJ, Rein-Weston A, Dosch S, Cosman D. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun. 2006;346:175–181. [PubMed]

37. Wills MR, Ashiru O, Reeves MB, Okecha G, Trowsdale J, Tomasec P, Wilkinson GW, Sinclair J, Sissons JG. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J Immunol. 2005;175:7457–7465. [PubMed]

38. Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M, Horwitz E, Prokocimer Z, Prichard M, Hahn G, Goldman-Wohl D, Greenfield C, Yagel S, Hengel H, Altuvia Y, Margalit H, Mandelboim O. Host immune system gene targeting by a viral miRNA. Science. 2007;317:376–381. [PubMed]

39. Desrosiers MP, Kielczewska A, Loredo-Osti JC, Adam SG, Makrigiannis AP, Lemieux S, Pham T, Lodoen MB, Morgan K, Lanier LL, Vidal SM. Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. Nat Genet. 2005;37:593–599. [PMC free article] [PubMed]

40. Lee SH, Girard S, Macina D, Busa M, Zafer A, Belouchi A, Gros P, Vidal SM. Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat Genet. 2001;28:42–45. [PubMed]

41. Scalzo AA, Fitzgerald NA, Simmons A, La Vista AB, Shellam GR. Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. J Exp Med. 1990;171:1469–1483. [PMC free article] [PubMed]

42. Scalzo AA, Lyons PA, Fitzgerald NA, Forbes CA, Yokoyama WM, Shellam GR. Genetic mapping of Cmv1 in the region of mouse chromosome 6 encoding the NK gene complex-associated loci Ly49 and musNKR-P1. Genomics. 1995;27:435–441. [PubMed]

43. Brown MG, Fulmek S, Matsumoto K, Cho R, Lyons PA, Levy ER, Scalzo AA, Yokoyama WM. A 2-Mb YAC contig and physical map of the natural killer gene complex on mouse chromosome 6. Genomics. 1997;42:16–25. [PubMed]

44. Depatie C, Muise E, Lepage P, Gros P, Vidal SM. High-resolution linkage map in the proximity of the host resistance locus Cmv1. Genomics. 1997;39:154–163. [PubMed]

45. Forbes CA, Brown MG, Cho R, Shellam GR, Yokoyama WM, Scalzo AA. The Cmv1 host resistance locus is closely linked to the Ly49 multigene family within the natural killer cell gene complex on mouse chromosome 6. Genomics. 1997;41:406–413. [PubMed]

46. Yokoyama WM, Plougastel BF. Immune functions encoded by the natural killer gene complex. Nat Rev Immunol. 2003;3:304–316. [PubMed]

47. Scalzo AA, Fitzgerald NA, Wallace CR, Gibbons AE, Smart YC, Burton RC, Shellam GR. The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J Immunol. 1992;149:581–589. [PubMed]

48. Vidal SM, Lanier LL. NK cell recognition of mouse cytomegalovirus-infected cells. Curr Top Microbiol Immunol. 2006;298:183–206. [PubMed]

49. Brown MG, Dokun AO, Heusel JW, Smith HR, Beckman DL, Blattenberger EA, Dubbelde CE, Stone LR, Scalzo AA, Yokoyama WM. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science. 2001;292:934–937. [PubMed]

50. Daniels KA, Devora G, Lai WC, O’Donnell CL, Bennett M, Welsh RM. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J Exp Med. 2001;194:29–44. [PMC free article] [PubMed]

51. Smith KM, Wu J, Bakker AB, Phillips JH, Lanier LL. Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J Immunol. 1998;161:7–10. [PubMed]

52. Coudert JD, Scarpellino L, Gros F, Vivier E, Held W. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood. 2008;111:3571–3578. [PubMed]

53. Orr MT, Sun JC, Hesslein DG, Arase H, Phillips JH, Takai T, Lanier LL. Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection. J Exp Med. 2009;206:807–817. [PMC free article] [PubMed]

54. Tassi I, Le Friec G, Gilfillan S, Takai T, Yokoyama WM, Colonna M. DAP10 associates with Ly49 receptors but contributes minimally to their expression and function in vivo. Eur J Immunol. 2009;39:1129–1135. [PMC free article] [PubMed]

55. Sjolin H, Tomasello E, Mousavi-Jazi M, Bartolazzi A, Karre K, Vivier E, Cerboni C. Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection. J Exp Med. 2002;195:825–834. [PMC free article] [PubMed]

56. Cheng TP, French AR, Plougastel BF, Pingel JT, Orihuela MM, Buller ML, Yokoyama WM. Ly49h is necessary for genetic resistance to murine cytomegalovirus. Immunogenetics. 2008;60:565–573. [PMC free article] [PubMed]

57. Fodil-Cornu N, Lee SH, Belanger S, Makrigiannis AP, Biron CA, Buller RM, Vidal SM. Ly49h-deficient C57BL/6 mice: a new mouse cytomegalovirus-susceptible model remains resistant to unrelated pathogens controlled by the NK gene complex. J Immunol. 2008;181:6394–6405. [PubMed]

58. Lee SH, Zafer A, de Repentigny Y, Kothary R, Tremblay ML, Gros P, Duplay P, Webb JR, Vidal SM. Transgenic expression of the activating natural killer receptor Ly49H confers resistance to cytomegalovirus in genetically susceptible mice. J Exp Med. 2003;197:515–526. [PMC free article] [PubMed]

59. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science. 2002;296:1323–1326. [PubMed]

60. Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, Naidenko OV, Iizuka K, Furukawa H, Beckman DL, Pingel JT, Scalzo AA, Fremont DH, Yokoyama WM. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A. 2002;99:8826–8831. [PubMed]

61. Adams EJ, Juo ZS, Venook RT, Boulanger MJ, Arase H, Lanier LL, Garcia KC. Structural elucidation of the m157 mouse cytomegalovirus ligand for Ly49 natural killer cell receptors. Proc Natl Acad Sci U S A. 2007;104:10128–10133. [PubMed]

62. Dokun AO, Kim S, Smith HR, Kang HS, Chu DT, Yokoyama WM. Specific and nonspecific NK cell activation during virus infection. Nat Immunol. 2001;2:951–956. [PubMed]

63. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature. 2009;457:557–561. [PMC free article] [PubMed]

64. Bubic I, Wagner M, Krmpotic A, Saulig T, Kim S, Yokoyama WM, Jonjic S, Koszinowski UH. Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol. 2004;78:7536–7544. [PMC free article] [PubMed]

65. Lodoen MB, Lanier LL. Viral modulation of NK cell immunity. Nat Rev Microbiol. 2005;3:59–69. [PubMed]

66. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675–678. [PubMed]

67. Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11:237–244. [PubMed]

68. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature. 1988;331:269–272. [PubMed]

69. Fahnestock ML, Johnson JL, Feldman RM, Neveu JM, Lane WS, Bjorkman PJ. The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity. 1995;3:583–590. [PubMed]

70. Abi-Rached L, Parham P. Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J Exp Med. 2005;201:1319–1332. [PMC free article] [PubMed]

71. Brown MG, Scalzo AA. NK gene complex dynamics and selection for NK cell receptors. Semin Immunol. 2008;20:361–368. [PMC free article] [PubMed]

72. Wilhelm BT, Gagnier L, Mager DL. Sequence analysis of the ly49 cluster in C57BL/6 mice: a rapidly evolving multigene family in the immune system. Genomics. 2002;80:646–661. [PubMed]

73. Voigt V, Forbes CA, Tonkin JN, Degli-Esposti MA, Smith HR, Yokoyama WM, Scalzo AA. Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc Natl Acad Sci U S A. 2003;100:13483–13488. [PubMed]

74. French AR, Pingel JT, Wagner M, Bubic I, Yang L, Kim S, Koszinowski U, Jonjic S, Yokoyama WM. Escape of mutant double-stranded DNA virus from innate immune control. Immunity. 2004;20:747–756. [PubMed]

75. Kielczewska A, Pyzik M, Sun T, Krmpotic A, Lodoen MB, Munks MW, Babic M, Hill AB, Koszinowski UH, Jonjic S, Lanier LL, Vidal SM. Ly49P recognition of cytomegalovirus-infected cells expressing H2-Dk and CMV-encoded m04 correlates with the NK cell antiviral response. J Exp Med. 2009;206:515–523. [PMC free article] [PubMed]

76. Lu X, Kavanagh DG, Hill AB. Cellular and molecular requirements for association of the murine cytomegalovirus protein m4/gp34 with major histocompatibility complex class I molecules. J Virol. 2006;80:6048–6055. [PMC free article] [PubMed]

77. LoPiccolo DM, Gold MC, Kavanagh DG, Wagner M, Koszinowski UH, Hill AB. Effective inhibition of K(b)- and D(b)-restricted antigen presentation in primary macrophages by murine cytomegalovirus. J Virol. 2003;77:301–308. [PMC free article] [PubMed]

78. Wagner M, Gutermann A, Podlech J, Reddehase MJ, Koszinowski UH. Major histocompatibility complex class I allele-specific cooperative and competitive interactions between immune evasion proteins of cytomegalovirus. J Exp Med. 2002;196:805–816. [PMC free article] [PubMed]

79. Holtappels R, Gillert-Marien D, Thomas D, Podlech J, Deegen P, Herter S, Oehrlein-Karpi SA, Strand D, Wagner M, Reddehase MJ. Cytomegalovirus encodes a positive regulator of antigen presentation. J Virol. 2006;80:7613–7624. [PMC free article] [PubMed]

80. Corbett AJ, Forbes CA, Moro D, Scalzo AA. Extensive sequence variation exists among isolates of murine cytomegalovirus within members of the m02 family of genes. J Gen Virol. 2007;88:758–769. [PubMed]

81. Dimasi N, Biassoni R. Structural and functional aspects of the Ly49 natural killer cell receptors. Immunol Cell Biol. 2005;83:1–8. [PubMed]

82. Hanke T, Takizawa H, McMahon CW, Busch DH, Pamer EG, Miller JD, Altman JD, Liu Y, Cado D, Lemonnier FA, Bjorkman PJ, Raulet DH. Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity. 1999;11:67–77. [PubMed]

83. Makrigiannis AP, Pau AT, Saleh A, Winkler-Pickett R, Ortaldo JR, Anderson SK. Class I MHC-binding characteristics of the 129/J Ly49 repertoire. J Immunol. 2001;166:5034–5043. [PubMed]

84. Michaelsson J, Achour A, Salcedo M, Kase-Sjostrom A, Sundback J, Harris RA, Karre K. Visualization of inhibitory Ly49 receptor specificity with soluble major histocompatibility complex class I tetramers. Eur J Immunol. 2000;30:300–307. [PubMed]

85. Bohm V, Simon CO, Podlech J, Seckert CK, Gendig D, Deegen P, Gillert-Marien D, Lemmermann NA, Holtappels R, Reddehase MJ. The immune evasion paradox: immunoevasins of murine cytomegalovirus enhance priming of CD8 T cells by preventing negative feedback regulation. J Virol. 2008;82:11637–11650. [PMC free article] [PubMed]

86. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med. 1989;320:1731–1735. [PubMed]

87. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood. 2004;104:3664–3671. [PubMed]

88. Guma M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L, Lopez-Botet M. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis. 2006;194:38–41. [PubMed]

89. Kuijpers TW, Baars PA, Dantin C, van den Burg M, van Lier RA, Roosnek E. Human NK cells can control CMV infection in the absence of T cells. Blood. 2008;112:914–915. [PubMed]

90. Brooks AG, Posch PE, Scorzelli CJ, Borrego F, Coligan JE. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J Exp Med. 1997;185:795–800. [PMC free article] [PubMed]

91. Chang C, Rodriguez A, Carretero M, Lopez-Botet M, Phillips JH, Lanier LL. Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily. Eur J Immunol. 1995;25:2433–2437. [PubMed]

92. Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med. 1991;173:1017–1020. [PMC free article] [PubMed]

93. Lazetic S, Chang C, Houchins JP, Lanier LL, Phillips JH. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J Immunol. 1996;157:4741–4745. [PubMed]

94. Vance RE, Jamieson AM, Raulet DH. Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. J Exp Med. 1999;190:1801–1812. [PMC free article] [PubMed]

95. Carretero M, Cantoni C, Bellon T, Bottino C, Biassoni R, Rodriguez A, Perez-Villar JJ, Moretta L, Moretta A, Lopez-Botet M. The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur J Immunol. 1997;27:563–567. [PubMed]

96. Houchins JP, Lanier LL, Niemi EC, Phillips JH, Ryan JC. Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C. J Immunol. 1997;158:3603–3609. [PubMed]

97. Le Drean E, Vely F, Olcese L, Cambiaggi A, Guia S, Krystal G, Gervois N, Moretta A, Jotereau F, Vivier E. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur J Immunol. 1998;28:264–276. [PubMed]

98. Palmieri G, Tullio V, Zingoni A, Piccoli M, Frati L, Lopez-Botet M, Santoni A. CD94/NKG2-A inhibitory complex blocks CD16-triggered Syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells. J Immunol. 1999;162:7181–7188. [PubMed]

99. Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity. 1998;8:693–701. [PubMed]

100. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998;187:813–818. [PMC free article] [PubMed]

101. Braud VM, Allan DS, O’Callaghan CA, Soderstrom K, D’Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795–799. [PubMed]

102. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, Geraghty DE. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A. 1998;95:5199–5204. [PubMed]

103. Aldrich CJ, DeCloux A, Woods AS, Cotter RJ, Soloski MJ, Forman J. Identification of a Tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen. Cell. 1994;79:649–658. [PubMed]

104. Braud V, Jones EY, McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol. 1997;27:1164–1169. [PubMed]

105. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol. 1998;160:4951–4960. [PubMed]

106. Llano M, Lee N, Navarro F, Garcia P, Albar JP, Geraghty DE, Lopez-Botet M. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol. 1998;28:2854–2863. [PubMed]

107. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, Cerundolo V, Borysiewicz LK, McMichael AJ, Wilkinson GW. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science. 2000;287:1031. [PubMed]

108. Ulbrecht M, Martinozzi S, Grzeschik M, Hengel H, Ellwart JW, Pla M, Weiss EH. Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol. 2000;164:5019–5022. [PubMed]

109. Wang EC, McSharry B, Retiere C, Tomasec P, Williams S, Borysiewicz LK, Braud VM, Wilkinson GW. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc Natl Acad Sci U S A. 2002;99:7570–7575. [PubMed]

110. Kaiser BK, Pizarro JC, Kerns J, Strong RK. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci U S A. 2008;105:6696–6701. [PubMed]

111. Browne H, Smith G, Beck S, Minson T. A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin. Nature. 1990;347:770–772. [PubMed]

112. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, Lopez-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 1997;186:1809–1818. [PMC free article] [PubMed]

113. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 1997;7:273–282. [PubMed]

114. Chapman TL, Heikeman AP, Bjorkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity. 1999;11:603–613. [PubMed]

115. Guma M, Budt M, Saez A, Brckalo T, Hengel H, Angulo A, Lopez-Botet M. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood. 2006;107:3624–3631. [PubMed]

Articles from Viruses are provided here courtesy of
Multidisciplinary Digital Publishing Institute (MDPI)